噻托溴铵联用沙美特罗/氟地卡松治疗中重度慢性阻塞性肺疾病缓解期患者30例疗效分析

Comparison of therapeutic effects of tiotropium inhalation capsules and SM/FP in patients with moderate-severe chronic obstructive pulmonary disease

目的研究噻托溴铵(思利华)联用沙美特罗/氟地卡松(舒利迭)治疗中重度慢性阻塞性肺疾病(COPD)缓解期患者的疗效及安全性。方法85名确诊为稳定期的中重度COPD患者随机分为三组:思利华组27例,舒利迭组28例及联合治疗组30例,分别使用思利华、舒利迭、思利华+舒利迭治疗。治疗前及治疗后1、3个月分别观察临床症状、生活质量评分、肺功能、病情变化及药物安全性。结果三组COPD患者经治疗后临床症状、生活质量评分及肺功能均有明显改善(P<0.05),而思利华及舒利迭联合治疗其改善作用更为显著(P<0.05)。其次,在减少加重病例、延缓病情发展的比较中,联合治疗明显优于单独药物治疗(P<0.05)。结论中重度COPD缓解期患者使用思利华及舒利迭联合吸入治疗可提高疗效及改善预后。

Objective To study the efficacy and safety of tiotropium irdaalation capsules and SM/FP （seretide） in patients with moderate -severe chronic obstructive pulmonary disease （COPD）. Methods 85 patients with stable moderate - severe COPD were randomly divided into 3 groups, 27 patients in tiotropium group, 28 in teretide group while 30 in combination group （tiotmpium ＋ teretide ）. Clinic symptom, life quality score, pulmonary function, number of severe exacerbations and safety were measured before and 1 month, 3 month after treatment. Results Clinic symptom, life quality score, pulmonary function were improved in all groups compare with those before treatment （ P 〈 0.05 ） , especially in combination group （ P 〈 0.05 ）. Besides, combination of tiotrpiurn and seretide reduced severe exacerbations and prolonged development of COPD exacerbations （ P 〈 0.05 ）. Conclu- sion The combination of tiotropium and seretide in patients with moderate - severe COPD can improve the efficacy and safety, while reduce severe exacerbations.